FindTrial
Sign In

Use of BIOCHIP mosaic slide to diagnose auto-immune blistering disorders

Comparison of conventional indirect immunofluorescence with BIOCHIP mosaic slide in the diagnosis of autoimmune bullous disorders-A cross-sectional study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/01/022752
Enrollment
100
Registered
2020-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L139- Bullous disorder, unspecified Health Condition 2: L14- Bullous disorders in diseases classified elsewhere Health Condition 3: L129- Pemphigoid, unspecified Health Condition 4: L109- Pemphigus, unspecified

Interventions

None listed

Sponsors

Raghavendra Rao
Lead Sponsor
Punya Suvarna
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All patients attending the OPD with a clinical and DIF diagnosis of AIBDs and who are willing to give consent for the study

Exclusion criteria

Exclusion criteria: Patients not willing to give consent for the study

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of BIOCHIP mosaic with conventional Indirect Immunofluorescence (IIF) test in the diagnosis of auto-immune bullous diseases (AIBDs).Timepoint: At baseline—

Secondary

MeasureTime frame
To compare the efficacy of BIOCHIP mosaic with conventional Indirect Immunofluorescence (IIF) test in the diagnosis of auto-immune bullous diseases (AIBDs).Timepoint: At 4 weeks after treatment—

Countries

India

Contacts

Public ContactRaghavendra Rao

Kasturba Medical College, Manipal

raghavrao1@gmail.com9845292640

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026